Bonesupport Holding is an orthobiologics company that develops and commercializes injectable bioceramic bone graft substitutes. Its products, based on the patented CERAMENT technology platform, remodel into the patient's own bone and can release antibiotics to support healing. The main products are CERAMENT BVF (Bone Void Filler), CERAMENT G (with Gentamicin), and CERAMENT V (with Vancomycin). These are used in clinical applications such as foot and ankle surgery, trauma, and arthroplasty, with potential future applications in spine. The company serves hospitals and clinics, with its primary markets being the United States and Europe, including the United Kingdom, Sweden, Germany, and other European countries. Founded in the early 2000s by Professor Lars Lidgren, the company focuses on replacing autografts with synthetic bone graft substitutes to improve patient outcomes.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Medical Devices Homepage bonesupport.com
Sector Healthcare IR page bonesupport.com/en
Tags
orthobiologics, bone graft substitutes, bioceramics, drug delivery, orthopedics, trauma, arthroplasty, foot and ankle, bone regeneration, CERAMENT, CERAMENT BVF, CERAMENT G, CERAMENT V
Press page bonesupport.com/en-us/media/press-releases

Metrics

Valuation  
Market cap kr 21.024B
Market cap (USD) $ 2.069B
P/E 77.41
PEG —
P/BV 24.24
P/S 17.90
P/OCF 95.00
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 17.8%
ROI 16.4%
ROIC 19.0%
Profit margin 12.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score 41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 1.175B 898.72M 591.07M 328.81M 212.88M 180.86M 155.462M 96.623M 129.301M 104.599M
Net profit 142.154M 133.754M 245.021M -68.167M -85.531M -101.41M -161.06M -176.405M -128.869M -110.19M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 189.9 335.49 100 71.01 36.4 — 32.5 18.78 20 —
Price performance 12m -0.43 2.35 0.41 0.95 -0.44 — 0.73 -0.06 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) — 32.1M 38.4M 62.6M 117M 196M 216M
↳ YoY growth +19.6% +63.0% +86.1% +68.1% +10.0%
↳ 5y CAGR +46.3%
Other receivables (SEK) — 5.32M 6.13M 7.96M 11M 19.4M 8.23M
Lease liabilities (SEK) — 10.5M 21.4M 17.5M 17.5M 14.6M 11.7M
Cash and deposits (SEK) 92.1M 354M 206M 201M 167M 227M 378M
Intangible assets (SEK) — 8.84M 8.37M 8.38M 12.2M — —
Right-of-use assets (SEK) — 11.8M 22.5M 18.9M 18.9M 15.7M 14.5M
Cash flow detail
Operating cash flow (SEK) — -100M -83.4M -47M -18.3M 65.8M 221M
Purchases of property, plant and equipment (SEK) — -346,000 -2.61M -1.96M -820,000 -1.53M -2.56M
Purchases of intangible assets (SEK) — -2.31M -808,000 -1.32M -5.24M -4.31M -2.63M
Change in receivables (cash effect) (SEK) — -2.92M -5.42M -26M -77.6M -95.4M -33.6M
Change in inventories (cash effect) (SEK) — -13.2M -117,000 7.08M -37.4M -22M -60.8M
Change in payables (cash effect) (SEK) — -1.41M 958,000 24.1M 17.4M 24.8M 25.4M
Interest paid (cash effect) (SEK) — -6,000 -1.17M -716,000 -3.12M -1.88M -468,000
Income taxes paid (cash effect) (SEK) — -4.97M -3.76M -2.69M -4.22M -4.8M -32.1M
Operating cash flow before change in receivables (SEK) — -97.4M -78M -21M 59.4M 161M 255M
Free cash flow (OCF - PPE - intangibles) (SEK) — -103M -86.8M -50.3M -24.3M 59.9M 216M
Income detail
Research and development expense (SEK) — 57.9M 53M 53.1M 57.1M 76M 91.4M
↳ 5y CAGR +9.6%
Total comprehensive income (SEK) — -102M -84.5M -65.9M 244M 139M 124M
Comprehensive income to owners (SEK) — -102M -84.5M -65.9M 244M 139M 124M
Reported — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Oct 26, 2026 12:58 PM

Regulatory

BONESUPPORT HOLDING AB (LEI CODE: 549300COLY053IGTLD63) ("BONESUPPORT") has during October 19, 2026 up to and including October 23, 2026 repurchased a total of 25,000 own ordinary shares (ISIN: SE0009858152) as part of the buy-back program initiated by BONESUPPORT on September 1, 2026.

The repurchases are part of the buy-back program of maximum SEK 100 million announced by BONESUPPORT on September 1, 2026 and which started on September 1, 2026 and will end no later than October 30, 2026. The buy-back program is carried out for the purpose of adapting BONESUPPORT’s capital structure to the company’s capital needs and thereby contribute to increased shareholder value. The repurchases are carried out in accordance with the Market Abuse Regulation (EU) 596/2014 ("MAR") and the European Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation").

Ordinary shares in BONESUPPORT have been repurchased as follows:

| Date | Aggregate daily volume (number of shares) | Weighted average price per day (SEK) | Total Daily Transaction Value (SEK) |

| October 19, 2026 | 5,000 | 250.4082 | 1,252,041 |

| October 20, 2026 | 5,000 | 250.9401 | 1,254,701 |

| October 21, 2026 | 5,000 | 252.6971 | 1,263,486 |

| October 22, 2026 | 5,000 | 306.2606 | 1,531,303 |

| October 23, 2026 | 5,000 | 325.9635 | 1,629,817 |

| Total during week 43 | 25,000 | 277.2539 | 6,931,347 |

| Total accumulated during buy-back program | 417,000 | 229.9840 | 95,903,333 |

All repurchases have been carried out on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) on behalf of BONESUPPORT. Following the above repurchases, BONESUPPORT's holding of treasury shares up to and including October 23, 2026 amounts to 790,320 ordinary shares and 905,155 Series C shares.

As of October 23, 2026, the total number of shares in BONESUPPORT, including treasury shares, is 66,764,350, of which 65,859,195 are ordinary shares and 905,155 are Series C shares. The total number of outstanding shares in BONESUPPORT, excluding treasury shares, is 65,068,875, all of which are ordinary shares.

Complete information about the transactions carried out in accordance with Article 5.3 of MAR and Article 2.3 of the Safe Harbour Regulation is attached to this press release.

Oct 22, 2026 6:00 AM

Regulatory

Interim Report

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2026.

"Strong growth and important progress in clinical evidence, commercialization, and regulatory work." Torbjörn Sköld, CEO

JULY - SEPTEMBER 2026

  • Net sales increased by 39 percent (38 percent at constant exchange rates) and amounted to SEK 408.8 million (294.1).

  • The US segment reported a sales growth of 40 percent (39 percent at constant exchange rate).

  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 35 percent (34 percent at constant exchange rates).

  • The gross margin amounted to 92.0 percent (92.9).

  • The adjusted operating result amounted to SEK 139.3 million (78.6). The reported operating result amounted to SEK 123.4 million (65.4).

  • Earnings per share before dilution were SEK 1.41 (0.52).

  • Earnings per share after dilution were SEK 1.39 (0.52).

JANUARY - SEPTEMBER 2026

  • Net sales increased by 26 percent (33 percent at constant exchange rates) and amounted to SEK 1,088.6 million (862.1).

  • The US segment reported a sales growth of 27 percent (35 percent at constant exchange rate).

  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 22 percent (25 percent at constant exchange rates).

  • The gross margin amounted to 91.7 percent (92.6).

  • The adjusted operating result amounted to SEK 328.3 million (180.7). The reported operating result amounted to SEK 285.1 million (149.9).

  • Earnings per share before dilution were SEK 3.47 (1.49).

  • Earnings per share after dilution were SEK 3.42 (1.47).

EVENTS DURING THE QUARTER

  • The US CMS (Centers for Medicare & Medicaid Services) confirmed the proposed DRG reassignment for CERAMENT G. The decision means that qualifying CERAMENT G cases will be assigned to the highest reimbursing DRG Groups within their respective clinical categories.

  • In August, the FDA extended the submission deadline for the additional data package for CERAMENT V. In September, the Company announced that the complete supplemental data package had been submitted to the FDA.

  • In September, the Company announced that its Board of Directors, pursuant to the authorization granted by the 2026 Annual General Meeting, resolved to initiate a share buy-back program of up to SEK 100 million for the purpose of adapting BONESUPPORT’s capital structure to the Company’s capital needs and thereby contribute to increased shareholder value. Pursuant to this, the Company repurchased a total of 268,000 own ordinary shares during September, for SEK 59.7 million.

  • In September, the Company announced a new distributor partnership with Stryker Australia Pty Ltd, which among other things includes entry into the New Zealand market.

  • In September, the SOLARIO study was published in The New England Journal of Medicine. The study demonstrates that systemic antibiotic treatment in orthopedic infections can be reduced from weeks to days without compromising outcomes when local antibiotic therapy is used. The findings support a potential paradigm shift in orthopedic infection management.

EVENTS AFTER THE PERIOD

  • Pursuant to the resolution by the Board of Directors in September to initiate a share buy-back program, the Company repurchased an additional total of 139,000 own ordinary shares during October. In total, 402,000 own shares have been repurchased for an amount corresponding to SEK 91.6 million out of a total of SEK 100 million.

Prompts

Bonesupport Holding (ticker BONEX), listed in Sweden.

ETFs Holding Bonesupport Holding

ETF Weight in ETF Shares Market value As of
AVDS 0.08% 8,911 $ 281.825K Nov 16, 2026
DFIS 0.02% 34,022 $ 1.077M Nov 12, 2026
DFIC 0.01% 42,180 $ 1.335M Nov 12, 2026
DFSI 0.01% 3,017 $ 95.479K Nov 12, 2026
DFAI 0.01% 30,923 $ 978.623K Nov 12, 2026
DFAX 0.00% 14,766 $ 467.301K Nov 12, 2026
AVDE 0.00% 14,077 $ 445.208K Nov 16, 2026